NCT03332173已完成2 期
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
BeiGene10 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2017年8月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
- 试验地点
- 10
- 主要终点
- Major Response Rate (MRR) as Assessed by the Independent Review Committee
研究概览
简要总结
This was a single-arm, multicenter Phase 2 study in Chinese participants with relapsed or refractory Waldenström's macroglobulinemia who exhibited one or more of the criteria for requiring treatment based on consensus guidelines from the Seventh International Workshop on Waldenström's Macroglobulinemia (IWWM). The study comprised an initial screening phase (up to 28 days), a single-arm treatment phase, and a follow-up phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical and definitive histologic diagnosis of WM, meeting at least one criterion for treatment according to consensus panel criteria from the Seventh IWWM.
- •WM pathology confirmation by central lab prior to study enrollment. Previous pathology report, concurrently with newly generated central lab report to be reviewed to support WM diagnosis.
- •Men and women ≥ 18 years of age.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Previously treated with a minimum of 1 prior line of standard chemotherapy-containing regimen (with completion of ≥ 2 continuous treatment cycles).
- •Documented failure to achieve at least minor response or documented disease progression after response to the most recent treatment regimen.
- •Neutrophils ≥ 0.75 x 10^9/L independent of growth factor support within 7 days of first dose.
- •Platelets ≥ 50 x 10^9/L, independent of growth factor support or transfusion within 7 days of first dose.
- •Hemoglobin ≥80 g/L, independent of erythropoietin (EPO) support or transfusion within 7 days of first dose of study drug.
- •Creatinine clearance of ≥ 30 mL/min (as estimated by the Cockcroft-Gault equation or estimated glomerular filtration rate [eGFR] from the Modification of Diet in Renal Disease [MDRD]).
- •Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x upper limit of normal (ULN).
- •Bilirubin ≤ 2 x ULN (unless documented Gilbert's syndrome).
- •International normalized ratio ≤ 1.5 and activated partial thromboplastin time ≤ 1.5 x ULN. Participants with lupus anticoagulant or acquired von Willebrand disease due to WM may be enrolled after discussion with the medical monitor.
- •ECHO must demonstrate left ventricular ejection fraction (LVEF) ≥50%.
- •Participants who relapse after autologous stem cell transplant may be enrolled if they are at least 6 months after transplant at screening. To be eligible after transplant, participants should have no active related infections.
- •Females of childbearing potential must agree to use highly effective forms of birth control throughout the course of the study and at least up to 90 days after last dose of study drug. Highly effective forms of birth control can be defined as abstinence, hysterectomy, bilateral oophorectomy with no menstrual bleeding for up to 6 months, intrauterine contraception, hormonal methods such as contraceptive injection, oral contraceptive, etc. Males must have undergone sterilization-vasectomy, or use a barrier method where the female partner uses the effective forms of birth control noted above and must not donate sperm for at least 90 days after last dose of study drug.
- •Life expectancy of > 4 months.
- •Able to provide written informed consent and can understand and comply with the requirements of the study.
排除标准
- •Central nervous system (CNS) involvement by WM.
- •Prior exposure to a BTK inhibitor.
- •Evidence of disease transformation.
- •Prior corticosteroids given in excess of prednisone 10 mg/day or its equivalent with antineoplastic intent within 7 days, prior chemotherapy, targeted therapy, or radiation therapy within 3 weeks, antineoplastic therapy with Chinese herbal medicine or antibody based therapies within 4 weeks of the start of study drug.
- •Major surgery within 4 weeks of randomization.
- •Toxicity of ≥ Grade 1 from prior anti-cancer therapy (except for absolute neutrophil count [ANC], platelets, and hemoglobin. For ANC, platelets, and hemoglobin, please follow inclusion criteria #7 [neutrophils], #8 [platelets], and #9 [hemoglobin]).
- •History of other active malignancies within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent.
- •Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any Class 3 or 4 cardiac disease as defined by the New York Heart Association (NYHA) Functional Classification, or history of myocardial infarction within 6 months of screening.
- •QTcF prolongation (defined as a QTc >480 msecs based on Fridericia's formula) or other significant ECG abnormalities including second degree atrioventricular (AV) block Type II, or third degree AV block.
- •Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
- •Active infection including infections requiring oral or intravenous anti-microbial therapy.
- •Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C infection (detected positive by polymerase chain reaction [PCR]).
- •Pregnant or lactating women.
- •Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, or put the study at risk.
- •On medications which are strong CYP3A inhibitors or strong CYP3A inducers.
- •History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
- •Has received allogenic hematopoietic stem cell transplantation prior to enrollment.
- •NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
Zanubrutinib
Experimental
Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity
干预措施: Zanubrutinib (Drug)
结局指标
主要结局
Major Response Rate (MRR) as Assessed by the Independent Review Committee
时间窗: Up to approximately 1 year and 9 months
MRR is defined as the percentage of participants who achieved complete response (CR) + very good partial response (VGPR) + partial response (PR), as assessed by an independent review committee according to modified Owen's criteria
次要结局
- DOMR: Event-free Rate(Up to approximately 1 year and 9 months)
- Progression Free Survival (PFS)(Up to approximately 1 year and 9 months)
- PFS: Event-free Rate(Up to approximately 1 year and 9 months)
- Overall Response Rate (ORR)(Up to approximately 1 year and 9 months)
- Duration of Major Response (DOMR)(Up to approximately 1 year and 9 months)
- Number of Participants With Resolution of Treatment-precipitating Symptoms(Up to approximately 1 year and 9 months)
- Number of Participants With an Anti-lymphoma Effect(Up to approximately 1 year and 9 months)
- Number of Participants With Adverse Events(Up to approximately 3 years and 5 months)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
4 期
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaNCT05687032Pfizer44
Enrolling By Invitation
2 期
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)cGvHDNCT06186804Abbisko Therapeutics Co, Ltd64
招募中
2 期
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsMSI-H/dMMR Solid TumorsNCT03736889BeiGene200
已完成
2 期
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRelapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic LymphomaNCT03206918BeiGene91
招募中
1 期
A Study of CM336 in Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT05299424Keymed Biosciences Co.Ltd48